Analysis of EQ-5D scores from two phase 3 clinical trials of romiplostim in the treatment of immune thrombocytopenia (ITP)

Value in Health

Volumn 14, Issue 1, 2011, Pages 90-96

  Sanz, Miguel A ^a   Aledort, Louis ^b   Mathias, Susan D ^c   Wang, Xuena ^d   Isitt, John J ^d  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c Health Outcomes Solutions   (United States)

^d AMGEN INC   (United States)

Author keywords

EQ 5D; Immune thrombocytopenia; Romiplostim; Utility

Indexed keywords

PLACEBO; ROMIPLOSTIM; FC RECEPTOR; HYBRID PROTEIN; THROMBOPOIETIN;

ADULT; AGE; ARTICLE; AUTOIMMUNE THROMBOCYTOPENIA; BLEEDING; BLEEDING TENDENCY; CHRONIC DISEASE; DATA ANALYSIS; DRUG EFFICACY; DRUG SAFETY; EQ 5D; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; SPLENECTOMY; THROMBOCYTE FUNCTION; CLINICAL TRIAL; COST BENEFIT ANALYSIS; ECONOMICS; EUROPE; HEALTH SURVEY; IDIOPATHIC THROMBOCYTOPENIC PURPURA; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; STATISTICAL MODEL; UNITED STATES;

ADULT; CHRONIC DISEASE; CLINICAL TRIALS, PHASE III AS TOPIC; COST-BENEFIT ANALYSIS; EUROPE; FEMALE; HEALTH STATUS INDICATORS; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, FC; RECOMBINANT FUSION PROTEINS; THROMBOPOIETIN; UNITED STATES;

EID: 79952671578     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2010.10.017     Document Type: Article

References (23)

1. Guide to the methods of technology appraisal. National Institute for Health and Clinical Excellence, June 2008. Available from: http://www.nice.org. uk [Accessed January 10, 2010].
2. Brooks R. EuroQol: the current state of play. Health Policy 1996;37:53-72. (Pubitemid 26191458)
3. Horsman J, Furlong W, Feeny D, Torrance G. The Health Utilities Index (HUI): concepts, measurement properties and applications. Health Qual Life Outcomes 2003;1:54.
4. Brazier JE, Roberts JF, Deverill MD. The estimation of a preference based measure of health from the SF-36. Health Econ 2002;21:271-92.
5. Brazier J, Roberts J, Tsuchiya A, et al. A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ 2004;13:873-84. (Pubitemid 39264234)
6. Grieve R, Grishchenko M, Cairns J. SF-6D versus EQ-5D: reasons for differences in utility scores and impact on reported cost-utility. Eur J Health Econ 2009:10: 15-23.
7. Bryan S, Longworth L. Measuring health-related utility: why the disparity between EQ-5D and SF-6D? Eur J Health Econ 2005:50: 253-60. (Pubitemid 41638849)
8. EQ-5D Value Sets: Inventory, Comparative Review and User Guide. Agota S, Oppe M, Devlin N, eds. EuroQol Group Monographs, Vol. 2. The Netherlands: Springer, 2007.
9. Cooper N, Bussel J. The pathogenesis of immune thrombocytopaenic purpura. Br J of Haematol 2006;133:364-74.
10. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009;113:2386-93.
11. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002;346:995-1008.
12. Rodeghiero F. Idiopathic thrombocytopenic purpura: an old disease revisited in the era of evidence-based medicine. J Hematol 2003;88:1081-7. (Pubitemid 37362537)
13. Cines DB, Bussel JB. How I treat idiopathic thrombocytopenic purpura (ITP). Blood 2005;106:2244-51. (Pubitemid 41510792)
14. Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008;371:395-403. (Pubitemid 351181334)
15. McMillan R, Bussel JB, George JN, et al. Self-reported healthrelated quality of life in adults with chronic immune thrombocytopenic purpura. Am J Hematol 2008;83:150-4.
16. George JN, Mathias SD, Go RS, et al. Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials. Br J Haematol 2009;144:409-15.
17. Snyder CF, Mathias SD, Cella D, et al. Burden of illness of immune thrombocytopenic purpura: impact on healthrelated quality of life. Curr Med Res Opin 2008;24;2767-76.
18. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996;88:3-40. (Pubitemid 26230668)
19. Shaw JW, Johnson JA, Coon SJ. US Valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care 2005;43:203-20. (Pubitemid 40353904)
20. British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of immune thrombocytopenic purpura in adults, children, and in pregnancy. Br J Haematol 2003;120:574-96.
21. Gernsheimer TB, George JN, Aledort LM, Tarantino MD, Sunkara U, Matthew Guo D, Nichol JL. Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP). J Thromb Haemost 2010;8:1372-82.
22. Ferreira PL, Ferreira LN, Pereira LN. How consistent are health utility values? Qual Life Res 2008;17:1031-42.
23. Szende A, Brazier J, Schaefer C, et al. Measurement of utility values in the UK for health states related to immune thrombocytopenic purpura. Curr Med Res Opin 2010;26:1893-903.